CNFINANCE ANNOUNCES THE RESULTS OF ITS EXTRAORDINARY GENERAL MEETING
GUANGZHOU, China, Dec. 10, 2025 /PRNewswire/ -- CNFinance Holdings Limited (NYSE: CNF) ("CNFinance" or the "Company"), a leading home equity loan service provider in China, today announced the results of its extraordinary general meeting of...
Autozi Internet Technology (Global) Ltd. Announces 50 for 1 Share Consolidation
BEIJING, Dec. 10, 2025 /PRNewswire/ -- Autozi Internet Technology (Global) Ltd. (Nasdaq: AZI) (the "Company" or "Autozi"), one of the leading and fast-growing lifecycle automotive service providers in China, today announced that the Company's board...
Sameh Samir Ali's Research Fund project is approved by National Natural Science Foundation of China (NSFC)
Is It Time to Learn from Termites? Hidden Yeasts Inside Nature's Micro-Bioreactor May Hold the Key ZHENJIANG, China, Dec. 9, 2025 /PRNewswire/ -- Recently, the National Natural Science Foundation of China (NSFC) approved Sameh Samir Ali's Research...
Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia 2025
HONG KONG, Dec. 9, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that data from the Phase II study (COMPASSION-25) for its first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with SOX regimen...
Binance Becomes First Crypto Exchange To Secure a Global License Under ADGM Framework, Setting a New Standard in Digital-Asset Regulation
ABU DHABI, UAE, Dec. 8, 2025 /PRNewswire/ -- Binance, the world's largest cryptocurrency exchange by trading volume and users, today announced a landmark regulatory achievement: The Financial Services Regulatory Authority (FSRA) of ADGM, the...
CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug Catalogue
SHANGHAI, Dec. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced today announced with great pleasure that its independently developed fully...
TransThera Publishes Clinical Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Lancet
NANJING, China and GAITHERSBURG, Md., Dec. 5, 2025 /PRNewswire/ -- TransThera Sciences Inc. ("TransThera") announced the publication of clinical results from a US-based Phase 2 trial evaluating tinengotinib in patients with Cholangiocarcinoma (CCA)...
NOTICE OF THE SETTLEMENT OF THE CLASS ACTION PROCEEDINGS RELATING TO LIGHTSPEED SECURITIES
Read this notice carefully as it may affect your rights. This notice is directed to all persons and entities, excluding certain persons associated with the defendants, who acquired securities of LIGHTSPEED COMMERCE INC. or LIGHTSPEED POS INC....
XPOVIO® Approved in Hong Kong for Two Additional Indications in Multiple Myeloma and Diffuse Large B-Cell Lymphoma
- XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the treatment for multiple myeloma (MM) when used together with dexamethasone (Xd), and its recent approvals as a monotherapy for...
Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class...